产品
编 号：F374163
分子式：C13H18O2
分子量：206.28
分子式：C13H18O2
分子量：206.28
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
280
In-stock
1g
360
In-stock
5g
760
In-stock
结构图
CAS No: 51146-56-6
产品详情
生物活性：
(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
体内研究：
(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.Animal Model:NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells
Dosage:15 mg/kg/day
Administration:Intraperitoneal injection; five days a week; for 4 weeks
Result:Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.
体外研究：
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM.
(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
体内研究：
(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.Animal Model:NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells
Dosage:15 mg/kg/day
Administration:Intraperitoneal injection; five days a week; for 4 weeks
Result:Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.
体外研究：
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent. (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 μM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 μM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1. (S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC50 of 61.7 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备